The Manufacturers Life Insurance Company Acquires New Position in Vaxcyte, Inc. $PCVX

The Manufacturers Life Insurance Company acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX) in the 2nd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 108,504 shares of the company’s stock, valued at approximately $6,307,000.

A number of other institutional investors also recently bought and sold shares of the company. Smartleaf Asset Management LLC boosted its holdings in Vaxcyte by 156.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock valued at $27,000 after purchasing an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its stake in shares of Vaxcyte by 1,463.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares during the period. EverSource Wealth Advisors LLC increased its holdings in shares of Vaxcyte by 33.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock worth $34,000 after buying an additional 184 shares during the last quarter. Capital Advisors Ltd. LLC purchased a new stake in shares of Vaxcyte during the 1st quarter valued at approximately $58,000. Finally, Allworth Financial LP purchased a new stake in shares of Vaxcyte during the 2nd quarter valued at approximately $75,000. 96.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on PCVX shares. Wall Street Zen upgraded Vaxcyte from a “strong sell” rating to a “sell” rating in a research report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Finally, Zacks Research upgraded Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Insider Transactions at Vaxcyte

In related news, CEO Grant Pickering sold 22,461 shares of the business’s stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $52.50, for a total value of $1,179,202.50. Following the sale, the chief executive officer owned 474,703 shares in the company, valued at approximately $24,921,907.50. The trade was a 4.52% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $56.33, for a total value of $126,742.50. Following the transaction, the chief operating officer directly owned 156,760 shares in the company, valued at approximately $8,830,290.80. The trade was a 1.42% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 118,396 shares of company stock valued at $6,459,390. Corporate insiders own 3.30% of the company’s stock.

Vaxcyte Stock Performance

Vaxcyte stock opened at $59.83 on Monday. The company’s 50 day simple moving average is $57.48 and its 200-day simple moving average is $55.99. Vaxcyte, Inc. has a 1 year low of $30.32 and a 1 year high of $65.00. The company has a market capitalization of $8.90 billion, a price-to-earnings ratio of -7.84 and a beta of 1.23.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.97) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.06) by $0.09. During the same quarter in the previous year, the firm posted ($1.22) EPS. Equities analysts expect that Vaxcyte, Inc. will post -7.6 earnings per share for the current year.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.